par Harradine, Kelly A;Ridd, Katie;Saunier, Elise F;Clermont, Frédéric ;Perez-Losada, Jesus;Moore, Dan H;Epstein, Ervin H;Bastian, Boris C;Akhurst, Rosemary J
Référence Clinical cancer research, 15, 16, page (5101-5107)
Publication Publié, 2009-08
Référence Clinical cancer research, 15, 16, page (5101-5107)
Publication Publié, 2009-08
Article révisé par les pairs
Résumé : | Nonmelanoma skin cancer incidence is enhanced >50-fold in patients taking antirejection drugs (ARD) following organ transplantation. Preclinical studies suggest that ARD treatment increases transforming growth factor-beta1 (TGF-beta1) levels, which contribute to enhanced tumor susceptibility independent of the immunosuppressive effects of ARDs. This study investigates whether TGF-beta signaling is elevated in transplant patients. |